← board
SEPN
Septerna, Inc.distress 0/10 · well-funded / low risk$33.41-2%today-12% from 52w high
Lead: hypoparathyroidism
Revenue
$27M
Liquidity
$522M
Runway
—
Shares 1y
+1%
Price & events
+25.3% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.3%
1D
+5.9%
1W
-8.6%
1M
+33.8%
3M
+29.7%
6M
+147.0%
1Y
—
2Y
—
5Y
+56.1%
All
Overview
- Market Cap
- $1.51B
- Volume
- 23.55K
- 52 Week Range
- $10.93 – $37.84
- Total Shares
- 45.08M
- Float Shares
- 23.11M
- Short %
- 13.82%
- % Held by Insiders
- 3.17%
- % Held by Institutions
- 102.62%
- RVOL
- 0.05x
Pipeline stages · 1 programs
SEP-631
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12-18 | Phase 1 | SEP-631 | Healthy Volunteers | 120 | completed |
Catalyst news & presentations · 15
- late 2026 or early 2027Guided 70%readoutPhase 1SEP-479 · Topline Phase 1 data anticipatedSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 2SEP-631 · Initiate Phase 2b trial in CSUSEC 8-K
- late 2026 / early 2027Guided 70%readoutPhase 1SEP-479 · topline Phase 1 dataSEC 8-K
- 2026-08-10Estimated 45%earningsEarningsEarnings releaseyahoo
- first half of 2026trial initiationsecondaryPhase 1SEP-479 · Planned initiation of Phase 1 clinical trialSEC 8-K
- first half of 2026readoutPhase 1SEP-631 · Initial SAD/MAD data from Phase 1 trialSEC 8-K
- March 2026conferencedata presentationsecondaryPhase 1SEP-631 · presentation of Phase 1 SAD/MAD results at AAAAI Annual MeetingSEC 8-K
- 2025trial initiationsecondaryPhase 1SEP-631 · Phase 1 initiation expectedSEC 8-K
- later this yeartrial initiationsecondarynext-generation PTH1R agonist · Plan to select and advance next-generation PTH1R candidate to clinicSEC 8-K
- third quarter of 2025trial initiationsecondaryPhase 1SEP-631 · Phase 1 clinical trial to assess safety, tolerability, PK, and PD in healthy volunteers.SEC 8-K
- 2025-07-01partnershipCollaboration and License Agreement with Novo Nordisk became effective.SEC 8-K
- mid-2025readoutPhase 1SEP-786 · SAD/MAD data expectedSEC 8-K
- 2025-05-13partnershipGlobal collaboration with Novo Nordisk for oral small molecule therapies targeting GPCRs, including GLP-1, GIP, and glucagon receptors.SEC 8-K
- 2025-03-03trial discontinuedSEP-786 · Discontinued Phase 1 SAD/MAD trial due to Grade 3 elevated unconjugated bilirubin events; reversible and no liver injury.SEC 8-K
- 2025-02-18safety signalSEP-786 · Two Grade 3 elevated unconjugated bilirubin events observed, reversible, no liver injury or SAEsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $45 (+35% upside) · 9 analysts
- 2026-07-01GuggenheimBuy
- 2026-07-01Truist SecuritiesBuy
- 2026-07-01HC Wainwright & Co.Buy
- 2026-06-08Raymond JamesStrong Buy
- 2026-05-13HC Wainwright & Co.Buy
- 2026-04-14HC Wainwright & Co.Buy
Competitors — hypoparathyroidism
Recent news
- 2026-07-17Septerna president & COO Elizabeth Bhatt sells $135,974 in stock - Investing.com
- 2026-07-17Form 4 Septerna Inc For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Septerna (SEPN) president sells 4,000 shares and exercises 4,000 options under plan - Stock Titan
- 2026-07-17Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates - MSN
- 2026-07-15Septerna, Inc. SEC Filing (Jul 15, 2026) - Stock Titan
- 2026-07-10Septerna (SEPN) Is Up 7.1% After Broad Russell Growth Index Additions Has The Bull Case Changed? - Sahm
- 2026-07-09Septerna Inc stock hits all-time high at 38.01 USD By Investing.com - Investing.com Nigeria
- 2026-07-09Septerna Inc stock hits all-time high at 38.01 USD - Investing.com
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.